leisure time -WSS

leisure time

author：entertainment 2025-09-28 07:21:53 - browse：46

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare proceeds with plan to claw back hospital funds

WSS

Live blog: Hearing on CRISPR

Novartis develops a rapidly manufactured CAR

How neuroscience research could help beat back brain cancer

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

FDA approves first blood sugar monitor without finger pricks

The health care issue Democrats can’t solve: hospital reform

focus

leisure time

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Prime Medicine says its gene editing passes test in monkeys

How to save PrEP access — and even expand it

Prime Medicine says its gene editing passes test in monkeys

Cancer drug shortages should be causing more outrage

How to convince healthy people to buy insurance

How one medical school became remarkably diverse

Prime Medicine says its gene editing passes test in monkeys

BioMarin wins approval for gene therapy to treat hemophilia A

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

focus

Statins reduce cardiovascular risk in people living with HIV

Where does female orgasm come from? Scientists think they know

Prime Medicine says its gene editing passes test in monkeys

Humans aren't the only ones with an imagination. Rats have it too

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

focus

hotspot

knowledge

focus